Terns Pharmaceuticals, Inc. announced the addition of three industry leaders as independent members of its board of directors. The new board members are David Fellows, Jeff Kindler and Jill M. Quigley. The appointment of the new directors to Terns’ board of directors became effective upon the recently announced closing of its $87 million Series C financing, at which time Elise Wang, Partner at Deerfield Management Company, also joined the board. Mr. Fellows was most recently the Chief Executive Officer of Nightstar Therapeutics. Jeff Kindler has more than three decades of business experience and has held leadership positions at some of the world’s most recognized companies. He is currently the CEO of Centrexion Therapeutics. Jill M. Quigley is currently the Chief Operating Officer at Passage Bio.